TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05882513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab and neoadjuvant therapy
Description: Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.~Non-squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1 ; pemetrexed 500mg/m2, day1 ; carboplatin AUC=5, i.v, day1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection of lung cancer
Description: radical resection of lung cancer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumour will be Collected from participant. Fate of sample is Destruction after use
Description: Tumour sample will be collected after surgery
Study: NCT04865679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axoguard Nerve Cap®
Description: Entubulation of the nerve stump into the Axoguard Nerve Cap® following surgical excision of symptomatic neuroma
Study: NCT05612516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of hydrogen peroxide levels in saliva using trays with reservoir.
Description: During bleaching using trays with reservoir.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of hydrogen peroxide levels in saliva using trays without reservoir.
Description: During bleaching using trays without reservoir.
Study: NCT05507814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Description: Participants will generate descriptions of vivid positive future events.
Study: NCT06543251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate continuous training group (MCT)
Description: Subject participating in 30-min sessions for 12 weeks and Each session consisted of a 10-min warm up, walking/running on a treadmill 30 minutes at 65-70% Maximum Heart rate and 10-min cool down.

Intervention type: OTHER
Group type: OTHER
Intervention: Sedentary control group (CON)
Description: The control group had normal daily life.
Study: NCT05123040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 MG Oral Tablet
Description: By mouth twice daily through day 56, then tapered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: 2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Dose level 1 (starting dose) = 1 mg/kg~* Dose level 2 = 0.5 mg/kg~* Dose level 3 = 0.25 mg/kg~* Dose level 4 = 0.1 mg/kg~* Dose level 5 = 0 mg/kg~  • If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:~* Dose level -1 = 1.5 mg/kg~* Dose level -2 = 2 mg/kg
Study: NCT05558007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: Daily oral administration of tadalafil 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: Daily oral administration of tadalafil 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BZ371A
Description: Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A
Description: Topical application of 1.5 mL of BZ371A in a concentration of 5mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral administration of a placebo pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Placebo
Description: Topical application of 1.5 mL of placebo
Study: NCT05507814

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Episodic Thinking
Description: Participants will generate descriptions of vivid positive future events.
Study: NCT05523102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol/acetaminophen
Study: NCT06448910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab (AK104)
Description: Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatin/cisplatin plus etoposide, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy + carboplatin/cisplatin plus etoposide), and finally consolidation therapy with cadonilimab (AK104) for 1 year.
Study: NCT06643975

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-piece zirconia dental implants
Description: One-piece zirconia dental implants with zirconia ball attachments, these implants are metal free made of oxide ceramics with cutting-edge Selective laser melting(SLM) surface treatment technology
Study: NCT05523102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Intravenous ketorolac/NSAID
Study: NCT06643975

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-piece titanium dental implants
Description: One-piece Titanium dental implants with titanium ball attachments, these implants are gold standard compatible implants
Study: NCT06650540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Plus Metronidazole Suppositories
Description: Administer a two-week course of Levofloxacin Plus Metronidazole Suppositories to patients diagnosed with chronic endometritis.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin co-administered with Metronidazole tablets
Description: Administer a two-week course of Levofloxacin in combination with Metronidazole tablets to patients diagnosed with chronic endometritis.
Study: NCT06649734

Intervention type: OTHER
Intervention: Delphi Study
Description: A Delphi study will be conducted with several rounds up to stable expert consensus or dissensus
Study: NCT01585090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: doing strengthening exercises of pelvic floor muscles

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: doing strengthening exercises of pelvic floor muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: doing strengthening exercises of pelvic floor muscles
Study: NCT05823285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS31903
Description: 0.01μg/kg-2.16 μg/kg QLS31903 for injection
Study: NCT05653557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shen Que Moxibustion
Description: Herb-partitioned moxibustion was administered at RN8 (Shen Que), once every 72 hours from the beginning of previous menstrual cycle day 2 until oocyte retrieval. Approximately 10 moxa cones will be used for this procedure, which will take approximately two hours. It is recommended that patients close their eyes during the procedure and rest. Following moxibustion, the umbilicus will be affixed and sealed with a medical applicator and removed after 24 hours.
Study: NCT06291857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant
Description: CIC will contain SARs-CoV-2 antigen (35 μg), tNIV antigens (2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains; 60 μg/strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novavax COVID-19 Vaccine
Description: Each 0.5 mL dose comprises 5 µg SARS-CoV-2 S protein and 50 µg Matrix-M adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tNIV Vaccine
Description: 2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains (60 μg/strain), and Matrix-M adjuvant (75 μg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High Dose
Description: Fluzone High-Dose is supplied as a suspension for IM injection 0.5 mL with 60 µg per strain
Study: NCT05700942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Dose Intervention-tsDCS
Description: Subjects will receive a high dose tsDCS (2.5mA, 30 mins) LT (4x/week, 5 weeks)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Intervention-tsDCS
Description: Subjects will receive a low dose tsDCS (2.5mA, 30 mins) LT (4xweek/ 5 weeks)
Study: NCT06470737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.2 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
Study: NCT04649008

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3T Magnetic Resonance Imaging
Description: Magnetic resonance imaging acquired at a field strength of 3 Tesla.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intracranial electroencephalography recordings
Description: Epilepsy patients may undergo implantation of intracranial electroencephalography (iEEG) electrodes for localization of epileptogenic foci, which also provide a means to record localized brain activity during memory or other tasks for research purposes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 7T Magnetic Resonance Imaging
Description: Magnetic resonance imaging acquired at a field strength of 7 Tesla.
Study: NCT06470737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMS-evoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.
Study: NCT06652126

Intervention type: OTHER
Intervention: Microbiological examinations.
Description: * BMR testing by rectal swab (combined with nasal swab in some centers) on admission to the ICU and weekly as part of routine care.~* Microbiological samples (blood cultures, respiratory and urinary samples, etc.) as part of routine care at the request of the clinicians in charge of the patient.

Intervention type: OTHER
Intervention: Microbiological examinations.
Description: * BMR testing by rectal swab (combined with nasal swab in some centers) on admission to the ICU and weekly as part of routine care.~* Microbiological samples (blood cultures, respiratory and urinary samples, etc.) as part of routine care at the request of the clinicians in charge of the patient.
Study: NCT06650956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated HPV and SRH Service Package
Description: 1. Integrated Service Package combines HPV vaccination with sexual and reproductive health (SRH) education. The vaccine in the intervention package is a single dose of recombinant Human Papilloma virus quadrivalent types, 6, 11, 16, and 18.;~2. The package will be delivered through multiple touch-points such as school-based programs, health facility services, and community outreach. i) In school, the intervention incorporates Comprehensive Sexuality Education, empowering boys and girls with knowledge about their bodies, health, and rights. This goes beyond simply providing information about HPV and vaccination. ii) At health facilities, the intervention package will also be delivered in adolescent-friendly ways, ensuring that boys and girls feel comfortable accessing SRH information. iii) Since not all boys and girls attend school, the intervention includes community outreach that ensures wider reach and accessibility for adolescents aged 10-13, including those not enrolled in school.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Description: The vaccine itself is not the intervention of interest as this is delivered in both intervention and comparison arms. The vaccine is a single dose of recombinant Human Papilloma Virus Quadrivalent (Types 6, 11, 16, and 18). The administration of the vaccine is an intramuscular injection of 0.5 mili liter of suspension form.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Description: The vaccine itself is not the intervention of interest as this is delivered in both intervention and comparison arms. The vaccine is a single dose of recombinant Human Papilloma Virus Quadrivalent (Types 6, 11, 16, and 18). The administration of the vaccine is an intramuscular injection of 0.5 mili liter of suspension form.
Study: NCT06653478

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT06653296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENX-102
Description: Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
Study: NCT05505591

Intervention type: DRUG
Intervention: Cangrelor
Description: Cangrelor administration during percutaneous coronary intervention for both chronic or acute coronary syndromes
Study: NCT06653296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENX-102
Description: Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENX-102
Description: Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period
Study: NCT06653296

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period
Study: NCT06652334

Intervention type: PROCEDURE
Intervention: Spinal anesthesia
Description: 20 patients undergoing spinal anesthesia

Intervention type: PROCEDURE
Intervention: Erector spinae plane block
Description: 20 patients undergoing erector spinae plane block
Study: NCT06653517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dosage: 150 mg orally, twice daily (total daily dose of 300 mg) Administration: Administer at approximately 12 hours apart. Take at the same time each day. If a dose is missed and less than 6 hours remain until the next dose, skip the missed dose. Do not open, crush, or break the capsules.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Dosage: 2 mg orally, once daily Administration: Administer at least 1 hour before or 2 hours after a meal. Take at the same time each day. If a dose is missed, it should be taken no later than 12 hours before the next scheduled dose; otherwise, skip the missed dose.~Usage in Combination: When used in combination with trametinib, trametinib should be taken once daily at the same time as either the morning or evening dose of dabrafenib to ensure synchronization of the treatment schedule.
Study: NCT06653452

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT and PET/MR scan, 68Ga-FAPI-04 PET/CT and PET/MR scan
Description: Patients with Locally Advanced Rectal Cancer underwent 68Ga-FAPI-04 PET/CT and PET/MR scan after injection of 0.02 to 0.04 mCi/Kg×patient weight (Kg). Within 1 week before and after the examination, 18F-FDG PET/CT and PET/MR is completed.
Study: NCT05981573

Intervention type: DEVICE
Intervention: ISF extraction device 1
Description: FDA approved microneedle attached to blotter paper tested for ability to extract 1ul of interstitial fluid

Intervention type: DEVICE
Intervention: ISF extraction device 1
Description: FDA approved microneedle attached to blotter paper tested for ability to extract 1ul of interstitial fluid

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo
Description: Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Electrochemical Assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo
Description: Measurement of Methadone and its metabolites in interstitial fluid with Liquid Chromatography - Mass Spectroscopy (LC-MS) and Electrochemical Assay

Intervention type: DEVICE
Intervention: Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo
Description: Measurement of Methadone and its metabolites in ISF with LC-MS and DPV

Intervention type: DEVICE
Intervention: Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo
Description: Measurement of Methadone and its metabolites in ISF with LC-MS and DPV

Intervention type: DRUG
Intervention: Measurement of Methadone in ISF before and after taking prescribed dose
Description: Measurement of methadone in ISF using DPV ex vivo versus in vivo . (Accuracy comparison - sensitivity, specificity, level of detection, and standard deviations )
Study: NCT04963504

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rest-to-exercise
Description: Pulmonary diffusing capacity is assessed at rest and during exercise (70% of VO2max on a bicycle ergometer)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sitting-to-supine
Description: Pulmonary diffusing capacity is assessed in the sitting and supine position
Study: NCT05981573

Intervention type: DRUG
Intervention: Measurement of Methadone in ISF before and after taking prescribed dose
Description: Measurement of methadone in ISF using DPV ex vivo versus in vivo . (Accuracy comparison - sensitivity, specificity, level of detection, and standard deviations )

Intervention type: DEVICE
Intervention: ISF Extraction Device 2
Description: Up to 15 minute periods of continuous ISF collection for analysis

Intervention type: DEVICE
Intervention: ISF Extraction Device 2
Description: Up to 15 minute periods of continuous ISF collection for analysis

Intervention type: DEVICE
Intervention: ISF Extraction Device 2
Description: Up to 15 minute periods of continuous ISF collection for analysis
Study: NCT05649787

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic training
Description: Supervised moderate to high-intensity interval aerobic training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic training
Description: Supervised moderate to high-intensity interval aerobic training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic training
Description: Supervised moderate to high-intensity interval aerobic training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic plus low to moderate-intensity strength training
Description: Supervised moderate to high-intensity interval aerobic training plus low to moderate-intensity strength training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic plus moderate to high-intensity strength training
Description: Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training
Study: NCT06599658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV) at baseline
Description: National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (IIV) at baseline
Description: National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines at a 3-month interval
Description: Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines at a 3-month interval
Description: Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine at Month 1
Description: National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine at Month 1
Description: National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines at a 6-month interval
Description: Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccines at a 6-month interval
Description: Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval
Study: NCT04907994

Intervention type: OTHER
Intervention: Cohort
Description: Nothing. Only implementation of a cohort with data collection via the SNDS.
Study: NCT06653400

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: paracervical block
Description: paracervical block with office hysteroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paracervical block
Description: paracervical block with office hysteroscopy
Study: NCT05448001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg
Description: JP-1366 20 mg 1 capsule, Lansoprazole 30 mg placebo 1 capsule before meal
Study: NCT06653400

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Dosage: 20 mL of 1% lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Dosage: 20 mL of 1% lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac
Description: Dosage: 2 mL (30 mg) of ketorolac
Study: NCT06649695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered via a subcutaneous injection (SC)
Study: NCT06652425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low temperature (16°C) group
Description: The exposure group will be exposed to low temperature (16°C) in a chamber for about 2 hours, resting during the whole periods.
Study: NCT05448001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 30mg
Description: JP-1366 20 mg placebo 1 capsule, Lansoprazole 30 mg 1 capsule before meal